News | May 15, 2022
Merck KGaA first quarter earnings grows on higher volumes, margins
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
India has the second-largest number of adults with diabetes globally, after China
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The company exports mobile surgery equipment to over 100 countries from Pune
Subscribe To Our Newsletter & Stay Updated
